Disclosed is a process of manufacturing cell spheroids using a bioink. More particularly, provided is a method of manufacturing a cell spheroid, the method including extruding a first bioink including an alginate; extruding a second bioink including cells into the extruded first bioink; adding a calcium chloride (CaCl2) solution to the alginate included in the first bioink; and dissolving the second bioink, present in the first bioink, in a cell culture medium to form a cell spheroid from the cells.

The present invention is directed towards methods of culturing pancreatic islet cells, with the methods comprising culturing pancreatic islet cells in the presence a cell culture medium while inhibiting the activity of Rho kinase (ROCK) in the cells during culturing.

Described herein are 3-dimensional clusters of reaggregated cells comprising cells reaggregated from at least two different cell sources, such as different cell types, different donors, and combinations thereof. Methods of making, using, and cryopreserving these 3-dimensional clusters of reaggregated cells are also described herein.

Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic -cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D -cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.

Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. Described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic -cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D -cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.

Described herein are 3-dimensional clusters of reaggregated cells comprising cells reaggregated from at least two different cell sources, such as different cell types, different donors, and combinations thereof. Methods of making, using, and cryopreserving these 3-dimensional clusters of reaggregated cells are also described herein.

Described herein are 3-dimensional clusters of reaggregated cells comprising cells reaggregated from at least two different cell sources, such as different cell types, different donors, and combinations thereof. Methods of making, using, and cryopreserving these 3-dimensional clusters of reaggregated cells are also described herein.

Disclosed herein are hepato-biliary-pancreatic organoid (HBPO or HBP organoid) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

Disclosed herein are hepato-biliary-pancreatic organoid (HBPO or HBP organoid) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

A microfluidic device is provided for culturing cell spheroids or organoids and therapeutics screening, the microfluidic device comprising a shell and an at least one sector, the shell comprising a multiplicity of segments, each segment defined by a center point, an outer wall, and radially extending walls that radiate from the center point to the outer wall, the sector retained in the segment and comprising a plurality of microwells, a loading well which is in elevated relationship with the plurality of microwells, a plurality of micro-troughs which extend between the loading well and the plurality of microwells, such that each microwell is in fluid communication with the loading well via a micro-trough, a delivery port, and a plurality of delivery troughs which extend between the delivery port and the plurality of microwells such that each microwell is in fluid communication with the delivery port via a delivery trough.